Short answer
Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events). One-time CEO bonus equal to 1.5% of Arbutus’ noncontingent Moderna settlement share, payable by end-July 2026.
Arbutus Biopharma Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- One-time CEO bonus equal to 1.5% of Arbutus’ noncontingent Moderna settlement share, payable by end-July 2026
- CEO entitled to 2.0% of remaining Moderna-related proceeds, including §1498 appeal or U.S. government litigation recoveries
- CEO entitled to 2.5% of proceeds from ongoing Pfizer/BioNTech patent litigation
- CFO receives 0.25% of noncontingent Moderna proceeds, including potential Genevant Parent dividend
- Future CFO bonus on remaining Moderna proceeds remains discretionary and terminable by Arbutus’ board
Item 8.01 · Other Events
- Patent-enforcement lawsuits filed against Pfizer/BioNTech and affiliates over lipid nanoparticle technology
- Genevant dividend expected in Q3 2026, but timing and terms remain uncertain
- Planned shareholder capital return of up to approximately $230 million through potential share repurchases
- Repurchases require Board approval and depend on receiving the Genevant Parent dividend
- Litigation outcomes, dividend receipt and capital return remain subject to material execution risks
Other items in this filing:
- Item 5.02: Departure/Election of Directors or Officers
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arbutus Biopharma Corp 8-K filings
Get the next ABUS 8-K as it lands
Follow ABUS for push alerts, or ask the research agent what this filing means.